Table.
Sputnik V | AZD1222 or Vaxzevria | Ad26.COV2·S or Janssen COVID-19 Vaccine | BNT162b2 or tozinameran or Comirnaty | mRNA-1273 or Moderna COVID-19 vaccine or Spikevax | |
---|---|---|---|---|---|
Type of vaccine | Adenovirus vector (Ad26 priming and Ad5 boost) | Adenovirus vector (nonreplicating chimpanzee adenovirus) | Adenovirus vector (Ad26) | mRNA in lipid nanoparticles | mRNA (part of virus genetic code) in lipid nanoparticles |
Efficacy | 91.6% | 62–90% | 66.3% | 95% | 94.5% |
Storage requirement | −18.5 °C (liquid form) 2–8 °C (dry form) |
2–8 °C | 2–8 °C | −70 °C ± 10 °C | −20 °C ± 5 °C |
Number of shots | X2 (3 weeks apart) | X2 (8–12 weeks apart) | X1 | X2 (3 weeks apart) | X2 (4 weeks apart) |
Cost per dose | $10 | $2.15 in the EU; $3–4 in the UK and U.S.; $5.25 in South Africa | $10 | $19.50 | $25-$37 |
Efficacy on variants | Unknown. Clinical trials were largely conducted in Russia prior to the emergence of major variants. Some data suggest reduced effect against the Beta and Gamma variants | Little effect against the Beta variant, but appears effective against Alpha and Gamma variants | Effective against the variants, although less so against Beta and Gamma variants | Lab data suggest “quite effective” against Alpha variant as well as Beta and Gamma variants | Lab data suggest “quite effective” against Alpha variant as well as Beta and Gamma variants |